Attendee search 

Immunicum AB (publ) develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, SUBCUVAX™ and INTUVAX®, in addition to the method for expansion of tumor-specific T-cells (CD70), are based on the Nobel Prize awarded discovery of dendritic cells (DCs) and their central role in all immune responses. Since the raw material consists of white blood cells (DCs) from healthy donors, Immunicum’s products can be mass-produced.

The therapeutic cancer vaccine INTUVAX® is injected intratumorally and is currently being evaluated in a clinical Phase I/II-study in metastatic renal cell carcinoma. It utilizes each patient’s own unique tumor tissue as antigen source and is thus a completely personalized therapeutic cancer vaccine that is still able to mass-produce and store in frozen condition for long periods of time.

  Cellectis is a biotechnology company that was founded in 1999 upon technology transferred from the Institut Pasteur, one of France’s leading institutions for science and health. The Cellectis stem cells Business Unit combines two Cellectis Group companies dedicated to stem celltechnology. These are Ectycell, based at the Evry Genopole (France), and Cellartis, based in Gothenburg (Sweden), which was acquired by Cellectis in October 2011. To find out more about Cellartis, please visit www.cellartis.com   The goal of the "Cellectis stem cells" Business Unit is to speed up the development of stem cell technology and in particular to find a robust and reproducible way of controlling stem cell production and differentiation, notably through the sharing of knowledge and expertise developed by the two companies, with a view to becoming a major, long-term and stable industrial player in the global marketplace.

Cellartis, a Swedish company founded in 2001, was formed as a spin-off from the University of Gothenburg. From its inception the company has worked on pluripotent stem cells and technologies applied to the search for new drugs, toxicity testing and regenerative medicine. Cellartis has proven expertise in many different areas including:

• controlling stem cell differentiation into liver and heart cells which offer unrivalled performance in toxicity testing applications;
• ownership and exploitation of the world's largest stem cell bank (30 proprietary lines);
• effective industrial rollout of their technologies;
• alongside leading partners, involvement in regenerative medicine programs which use the immense potential of stem cells for the restoration of damaged tissues and organs.

The Cellectis stem cells Business Unit has ambitious objectives.

• To industrialize pluripotent stem cells;
• To develop industrial in vitro tools predictive of human physiology and genetic diversity, such as tools for the drug and cosmetic industries, as well as for research, and that can be immediately used in industrial molecular screening and selection processes;
• To develop major partnerships, particularly in the field of regenerative medicine;
• To take a strategic industrial role in order to set standards in an emerging market, forge a strong pioneering position in the areas of focus, and build a genuine industrial sector based around stem cells and a competitive industrial cluster.

Red Glead Discovery has two main business areas: CRO services and internal early drug discovery projects. Our focus is on the development of drugs based on small molecules and peptides.

Our first-rate drug discovery services include integrated lead discovery, based on competence and long-standing experience. In-house laboratory capabilities comprise medicinal chemistry, assay development and screening, radioisotope-labelling, analytical chemistry, in vitro profiling and NMR.

An expert area is generation of chemical starting points for drug targets and to develop them into patentable lead compounds with drug-like properties and low risk profile. Our project management skills and cross-disciplinary capabilities make us a preferred partner for clients that want to develop compounds with high potential to become successful drugs.